Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Dermatol Clin ; 31(4): 679-94, x, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-24075553

RESUMO

In addition to its traditional use for the evaluation of skin tumors, dermoscopy continuously gains appreciation in other fields of dermatology. The patterns of several inflammatory and infectious skin diseases have already been described, and dermoscopy has been shown to improve the clinical diagnostic performance in the daily practice. The increasing use of dermoscopy was significantly enhanced by the development of the new generation hand-held dermatoscopes that can be easily placed in every dermatologist's pocket and do not require the use of immersion fluid. In this article, we provide an up-to-date summary of data on dermoscopy in general dermatology.


Assuntos
Dermatite/diagnóstico , Dermatologia , Dermoscopia/instrumentação , Dermoscopia/métodos , Dermatopatias/diagnóstico , Dermatite/imunologia , Dermatite/patologia , Humanos , Dermatopatias/imunologia , Dermatopatias/patologia
5.
J Clin Pathol ; 66(5): 441-5, 2013 May.
Artigo em Inglês | MEDLINE | ID: mdl-23463675

RESUMO

BRAF V600R-M-D are uncommon mutations, not included in the experimental protocols of BRAF selective inhibitors. We report the evaluation of correlations among different types of BRAF somatic mutations in melanoma and their management with BRAF inhibitors. 21 patients with BRAF mutated metastatic melanoma were enrolled in the protocol with BRAF inhibitors for compassionate use at the University of Modena. Hot spot V600E mutations were found in 19 patients. V600R mutation and double (V600E -V600M) mutation were identified in two melanomas. In one case, V600K mutation was found. Two screening failures were noted. Mean progression free survival at follow-up of to 8 weeks, was 7.6 months. Five patients had a very short follow-up and the experimental protocol is still ongoing, so we cannot provide complete follow-up data. However, all of them are still under treatment and disease progression free. An objective response with few side effects was observed in all patients. in vitro studies with the aim of testing drug sensitivity.


Assuntos
Antineoplásicos/uso terapêutico , Melanoma/tratamento farmacológico , Melanoma/genética , Mutação , Proteínas Proto-Oncogênicas B-raf/genética , Neoplasias Cutâneas/tratamento farmacológico , Neoplasias Cutâneas/genética , Sequência de Bases , Ensaios de Uso Compassivo , Feminino , Humanos , Imidazóis/uso terapêutico , Indóis/uso terapêutico , Masculino , Melanoma/patologia , Pessoa de Meia-Idade , Dados de Sequência Molecular , Estadiamento de Neoplasias , Oximas/uso terapêutico , Proteínas Proto-Oncogênicas B-raf/antagonistas & inibidores , Neoplasias Cutâneas/patologia , Sulfonamidas/uso terapêutico , Vemurafenib
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA